First Marijuana-Derived Epilepsy Drug Tops AJPB Week in Review

Top news of the week from The American Journal of Pharmacy Benefits.

5. Study: African Americans Remain Disproportionately Affected by HIV

African Americans are more likely to be diagnosed with HIV compared with other groups, according to an analysis published in the Journal of Racial and Ethnic Health Disparities. Read more.

4. New Data Show Oral Semaglutide Significantly Reduced A1C in Adults with Type 2 Diabetes

Newly published findings from the PIONEER 1 phase 3a trial show that once-daily once-daily oral semaglutide was associated with significant reductions in blood sugar in adults with type 2 diabetes. Read more.

3. Autism Risk in Children Higher in Mothers with Type 1 Diabetes

The risk of autism spectrum disorder (ASD) in children was higher in mothers with type 1 diabetes (T1D) diagnosed by 26 weeks’ gestation, according to a new research letter in JAMA. Read more.

2. Combo Therapy for Advanced BRAF-Mutant Melanoma Gets FDA Approval

The FDA has granted approval to Array BioPharma’s encorafenib (Braftovi) capsules in combination with binimetinib (Mektovi) tablets for the treatment of patients with unresectable or metastatic melanoma with BRAFV600E or BRAFV600K mutation. Read more.

1. FDA Approves First Marijuana-Derived Epilepsy Treatment

The FDA has approved a cannabidiol (CBD) treatment for 2 rare and severe forms of epilepsy, making it the first FDA-approved medication that contains a purified drug substance derived from marijuana. Read more.